Dexmedetomidine Increases Hippocampal Phosphorylated Extracellular Signal–regulated Protein Kinase 1 and 2 Content by an α2-Adrenoceptor–independent Mechanism

Authors:

Abstract
DEXMEDETOMIDINE is a potent and highly selective agonist of the α2-adrenergic receptors with a broad spectrum of actions on the human brain, including clinical sedation, anesthetic-sparing effects, and analgesia.1–5 Besides its action at α2-adrenergic receptors, dexmedetomidine also exhibits some affinity for imidazoline binding sites.6–8 Recent experimental work indicates that dexmedetomidine also exhibits more long-term effects on the brain, such as neuroprotection against ischemic injury.9–14 We have shown that dexmedetomidine reduces the severity of excitotoxic brain injury in the perinatal period in mice.9 Well-designed experiments performed in knockout animals have shown that this effect is mediated by the activation of the α2A-adrenoceptor subtype.10,11 These neuroprotective properties of dexmedetomidine most likely proceed via activation of intracellular signaling cascades, while an indirect effect through a reduction in the release of glutamate or catecholamines cannot be ruled out.12,13 We have shown that dexmedetomidine preconditions brain tissue against ischemic cell death and caspase-3 expression in hippocampal slices subjected to oxygen glucose deprivation.14 This effect is mediated in part by an increase in phosphorylation of focal adhesion kinase, a nonreceptor tyrosine kinase coupling rapid events such as ligand–receptor interactions, or action potential propagation, to long-lasting changes in synaptic plasticity.15 Also, dexmedetomidine exerts synergistic neuroprotective effects with xenon that have been observed 30 days after ischemic injury.16

This publication has 44 references indexed in Scilit: